Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.81 |
| ▸ | HSP90AB1 | P08238 | 10/20 | 0.81 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29974145 | 0.99 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| Hydrochloric Acid SCHEMBL23673784 | 0.99 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL30829342 | 0.91 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| Onalespib SCHEMBL382780 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| Onalespib SCHEMBL29351356 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL384367 | 0.90 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL30368762 | 0.89 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL25317452 | 0.89 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL1205611 | 0.89 | HSP90AA1 (0.86) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| Onalespib SCHEMBL1205801 | 0.89 | HSP90AA1 (0.98) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136614-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | MAGICBULLETTHERAPEUTICS CO., LTD. (KR) | 2025-05-01 | — | — | US | disclosed |
| EP-4442691-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | Magicbullettherapeutics Co., Ltd. (KR) | 2024-10-09 | — | — | EP | disclosed |
| CN-118613486-A | 2, 7-Substituted pyrrolo [2,1-F ] [1,2,4] triazine compounds having protein kinase inhibitory activity | 魔法弹丸治疗 | 2024-09-06 | — | — | CN | disclosed |
| US-20220184217-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2022-06-16 | — | — | US | disclosed |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-02-03 | — | — | US | disclosed |
| WO-2021202830-A2 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20210145971-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2021-05-20 | — | — | US | disclosed |
| US-20210000966-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2021-01-07 | — | — | US | disclosed |
| WO-2020205948-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2019195384-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019118830-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000966-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 3/4885 |
| US-20250136614-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | STK25, MAP3K15, MAP3K5 | HSP90AA1 1399/4885HSP90AB1 1468/4885HSP90B1 2214/4885 |
| US-20220184217-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 2/4885 |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 3/4885 |
| US-20210145971-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.